araag2/HINT huggingface dataset:
Clinical trial NCT00377936 (phase 2, status: completed)
Conditions: adenocarcinoma, metastasis, pancreas neoplasms
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: gemcitabine alone, endotag-1 and gemcitabine, endotag-1 and gemcitabine, endotag-1 and gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Inoperable adenocarcinoma of the pancreas

          -  Histologic or cytologic confirmation

          -  At least 18 years of age

        Exclusion Criteria:

          -  Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrollment

          -  Major surgery within 4 weeks prior to enrollment

          -  Major cardiovascular disease
Clinical trial NCT00422422 (phase 2, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of epilepsy

          -  Subject having at least 1 seizure (any type) during the 3 weeks before first visit

          -  Stable dosing of 1-3 concomitant antiepileptic drugs

        Exclusion Criteria:

          -  Pregnant or nursing females

          -  Concomitant use of Levetiracetam

          -  Epilepsy secondary to a Progressive cerebral disease/tumor or other neurodegenerative
             disease

          -  History of status epilepticus

          -  Clinically significant acute or chronic illness, underlying disease or medication
             condition

          -  History of suicide attempt
Clinical trial NCT00458016 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mb07803, placebo
SMILES: CCOC(=O)C(C)(C)NP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(O1)C1=C(SC(N)=N1)C(=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting plasma glucose between 120 - 270 mg/dL at screening

          -  HbA1c measurements between 6.0 - 10% at screening

          -  Females who are surgically sterile (i.e. women who have had a hysterectomy or tubal
             ligation). Females who are postmenopausal for at least 12 consecutive months and
             documented by blood follicular stimulating hormone (FSH) greater than or equal to 40
             mlU/mL.Females of childbearing potential must be willing to use an approved
             double-barrier method of birth control (e.g. condom plus spermicide ;IUD plus
             spermicide) from the time of signing the informed consent form through 4 weeks
             following the last dose of study drug.

          -  Body mass index (BMI) in the range of 18.5 - 37 kg/m2 Patients with a BMI in the range
             of 37.5 - 40 kg/m2 who in the Investigator's opinion, are in good health and satisfy
             the eligibility criteria, will be considered on a case-by case basis

          -  Written informed consent

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Type 2 diabetes mellitus with a history of diabetic ketoacidosis or ketosis-prone

          -  Use of thiazolidinediones (TZDs)

          -  Currently on more than two oral hypoglycemic agent

          -  History of outpatient insulin use

          -  Clinically significant history of cardiac disease within 6 months of informed consent
Clinical trial NCT00698516 (phase 2, status: completed)
Conditions: recurrent small-cell lung cancer (sclc), lung cancer, small cell
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: oral hycamtin (topotecan) capsules + iv avastin (bevacizumab)
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of SCLC.

          -  First recurrence of SCLC after therapy with one prior chemotherapy regimen at initial
             diagnosis.

          -  Relapsed SCLC of any duration (both sensitive and resistant relapse).

          -  ECOG performance status of </= 2.

          -  Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.

          -  No prior therapy with bevacizumab or any other VEGF inhibitor or topotecan

        Exclusion Criteria:

          -  Uncontrolled emesis, regardless of etiology.

          -  Active uncontrolled infection.

          -  GI conditions or drugs that could impact absorption of oral topotecan.

          -  Known hypersensitivity to any component of topotecan capsule or compounds chemically
             related to topotecan.

          -  Uncontrolled hypertension with BP>150/100.

          -  Prior h/o hypertensive crisis or encephalopathy.

          -  NYHA Grade II or greater congestive heart failure.

          -  H/O myocardial infarction within 6 months.

          -  H/O stroke or TIA within 6 months.

          -  H/O thrombotic or hemorrhagic disorders.

          -  Clinically significant vascular disease (e.g., aortic aneurysm requiring surgical
             repair or recent peripheral arterial thrombosis) within 6 months.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.

          -  Anticipation of need for major surgical procedure during the study.

          -  Minor surgical procedures within 7 days prior to treatment start (placement of
             vascular access devices is permitted).

          -  H/O abdominal fistula, GI perforation, or intra-abdominal abscess within prior 6
             months. Serious, non-healing wound, active ulcer, or untreated bone fracture. - H/O
             hemoptysis within prior 1 month.

          -  Concurrent radiotherapy.

          -  H/O whole lung radiation within 90 days prior to start of treatment.

          -  Presence or h/o central nervous system or brain metastases.

          -  H/o another malignancy other than SCLC.

          -  Concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment
             of small cell lung cancer.
Clinical trial NCT00191672 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, paclitaxel, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced or metastatic breast cancer

          -  Disease that can be measured by the physician or radiologic test.

          -  May have had one chemotherapy treatment for advanced or metastatic disease.

          -  Patients may have received any prior adjuvant chemotherapy, including taxane
             containing regimens, provided this treatment was completed at least 6 months prior to
             enrollment.

          -  Patients may have received prior hormone therapy or immunotherapy.

        Exclusion Criteria:

          -  Patients with only non-measurable disease

          -  Cancer that has spread to the brain

          -  A patient who received a taxane with metastatic disease.

          -  Pregnancy

          -  Patients who received prior gemcitabine
Clinical trial NCT00399802 (phase 2, status: completed)
Conditions: breast cancer, metastatic bone disease
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: za, odanacatib, odanacatib matching placebo, za matching placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has histologically or cytologically-confirmed breast cancer

          -  Patient has documented skeletal metastases

        Exclusion Criteria:

          -  Patient is undergoing current oral bisphosphonate therapy, or has a history of oral
             bisphosphonate use within 6 months of entry into study
Clinical trial NCT00292396 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: anti il-12 monoclonal antibody/abt-874, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent
             stable medical history.

          -  Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate
             to severe plaque psoriasis

        Exclusion Criteria:

          -  Subject had previously received systemic or biologic anti-IL-12 therapy

          -  Subject cannot discontinue systemic therapies and/or topical therapies for the
             treatment of psoriasis and cannot avoid UVB or PUVA phototherapy

          -  Subject is taking or requires oral or injectable corticosteroids

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate
             for the study

          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant
Clinical trial NCT00510887 (phase 2, status: terminated)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bortezomib, rituximab, fludarabine, mitoxantrone, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory
             disease to at least one prior regimen.

          -  No prior bortezomib therapy.

          -  Voluntary written informed consent.

          -  Female subject is either post-menopausal or surgically sterilized or willing to use an
             acceptable method of birth control.

          -  Male subject agrees to use an acceptable method for contraception for the duration of
             the study therapy.

          -  18 years of age or older.

          -  aspartate aminotransferase (AST),alanine aminotransferase (ALT), total bilirubin < 3
             times the upper limit of normal unless documented by the treating physician to be
             secondary to underlying lymphoma.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

        Exclusion Criteria:

          -  Platelet count of < 50,000 within 14 days before enrollment unless documented by the
             treating physician to be due to the disease.

          -  Absolute neutrophil count of < 1000 within 14 days before enrollment unless documented
             by the treating physician to be due to disease.

          -  Estimated or measured creatinine clearance of less than 30 ml/min within 14 days
             before enrollment.

          -  ≥Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia.

          -  Patient has hypersensitivity to boron, mannitol or any drug included in the current
             protocol.

          -  Female subject is pregnant or lactating.

          -  Received other investigational drugs for this disease within 14 days of enrollment

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Known HIV+ status.

          -  Cardiac ejection fraction less than 35% at study entry measured by echocardiogram,
             Multigated Acquisition (MUGA) or cardiac MRI.
Clinical trial NCT00658619 (phase 2, status: completed)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: 400 µg brimonidine tartrate implant, 200 µg brimonidine tartrate implant
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Geographic atrophy in both eyes due to age-related macular degeneration

          -  Visual acuity between 20/40 to 20/320

        Exclusion Criteria:

          -  Known allergy to brimonidine

          -  Uncontrolled systemic disease or infection of the eye

          -  Recent eye surgery or injections in the eye

          -  Female patients who are pregnant, nursing or planning a pregnancy
Clinical trial NCT01549834 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: abt-126, abt-126, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The subject and caregiver must voluntarily sign and date an informed consent. If the
             subject does not have the capacity to provide informed consent, full informed consent
             must be obtained from the subject's representative and assent must be obtained from
             the subject.

          -  The subject is a male or female between the ages of 55 and 90 years, inclusive, at
             Screening Visit 1. Main Inclusion (Continued):

          -  The subject meets the Neurological and Communicative Disorders and Stroke/Alzheimer's
             Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD.

          -  The subject must be receiving a stable dose of an AChEI (donepezil or rivastigmine)
             for at least 90 days prior to Screening Visit 1.

          -  The subject has a Mini-Mental Status Examination (MMSE) total score of 12 to 24,
             inclusive, at Screening Visit 1.

          -  The subject has a Cornell Scale for Depression in Dementia (CSDD) score ≤ 10 at
             Screening Visit 1.

          -  The subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4 at Screening
             Visit 1.

          -  With the exception of a diagnosis of mild-to-moderate Alzheimer's disease and the
             presence of stable medical conditions, the subject is in general good health, based
             upon the results of medical history, physical examination, vital signs, laboratory
             profile, and a 12-lead electrocardiogram (ECG).

          -  The subject has an identified, reliable caregiver who will provide support and ensure
             compliance with the study medication and procedures, and provide accurate information
             about the subject's status during the study.

        Exclusion Criteria:

          -  The subject has taken galantamine or memantine within 60 days prior to Screening Visit
             1.

          -  The subject has received excluded concomitant medications.

          -  The subject has clinically significant abnormal laboratory values at Screening Visit 1
             as determined by the investigator.

          -  The subject has a history of any significant neurologic disease other than Alzheimer's
             disease including Parkinson's disease, multi-infarct or vascular dementia,
             Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy,
             multiple sclerosis, any seizures, mental retardation or a history of significant head
             trauma followed by persistent neurologic deficits or known structural brain
             abnormalities.

          -  In the opinion of the investigator, the subject has any clinically significant
             uncontrolled medical or psychiatric illness.
Clinical trial NCT00226811 (phase 2, status: completed)
Conditions: stomach neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: sunitinib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Gastric or gastroesophageal junction adenocarcinoma cyto/histologically documented

          -  Disease progression/ recurrence after treatment with one prior single agent or
             combination chemotherapy regimen for advanced / metastatic disease (last dose at least
             4 wks before study entry). Patients may have also received prior adjuvant therapy if
             recurrence occurred > 6 months after adjuvant therapy completion

          -  Evidence of measurable disease by radiographic technique

          -  Adequate organ function.

        Exclusion Criteria:

          -  Clinically relevant ascites (i.e. requiring paracentesis)

          -  Severe weight loss

          -  NCI CTCAE Grade 3 hemorrhage <4 weeks of starting study treatment

          -  Diagnosis of second malignancy within last 3 years

          -  History of or known brain metastases, spinal cord compression, or carcinomatous
             meningitis

          -  Known HIV

          -  Serious acute or chronic illness

          -  Current treatment on another clinical trial

          -  Pregnant or breastfeeding
Clinical trial NCT01563523 (phase 2, status: completed)
Conditions: acquired bleeding disorder, trauma
ICD codes: D68.311, L85.0, H53.62, I77.0, L11.0, L68.1, N48.83, K08.81, K08.82, O71.9, N48.31, O71.89, G89.11, G89.21
Drugs: activated recombinant human factor vii, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained from the subject and/or his/her legally authorised
             representative (LAR) before any trial-related activities

          -  Injury(ies) due to a blunt and or penetrating trauma

          -  Receipt of 6 units of PRBC within a 4 hour period following admittance to the trauma
             centre

          -  Receipt of 8 units of PRBC upon administration of trial drug

        Exclusion Criteria:

          -  Prehospital cardiac arrest

          -  Cardiac arrest in the ER or OR

          -  Gunshot wound to the head

          -  Glasgow Coma Scale below 8

          -  Base deficit of above 15 mEq/l or severe acidosis

          -  Transfusion of 8 units or more of PRBC prior to arrival in trauma centre
Clinical trial NCT01465230 (phase 2, status: terminated)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: maintenance lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    this study was unsuccessful in enrolling the target number of subjects during the funding
    period.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Previous induction treatment with bendamustine and rituximab

          -  18 or more years of age

          -  chronic lymphocytic leukemia

          -  ECOG performance status less than or equal to 2

          -  Absolute neutrophile count more than 1,000

          -  Platelet count more than 70,000

        Exclusion Criteria:

          -  Serious medical condition that would prevent treatment with lenalidomide

          -  Evidence of tumor lysis syndrome

          -  Any prior treatment with lenalidomide
Clinical trial NCT01336465 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: placebo, rhumab beta7
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of moderate to severe ulcerative colitis outpatient

          -  Disease duration at time of screening of >/= 12 weeks

        Exclusion Criteria:

          -  Extensive colonic resection or subtotal or total colectomy

          -  Presence of an ileostomy or colostomy

          -  Moderate to severe anemia

          -  A history or evidence of colonic mucosal dysplasia

          -  Pregnant or lactating

          -  Significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary,
             renal, hepatic, endocrine, or gastrointestinal (GI) disorders

          -  Significant screening ECG abnormalities, including evidence of acute myocardial
             infarction, complete left bundle branch block, second-degree heart block, or complete
             heart block

          -  Poorly controlled diabetes

          -  Impaired renal function

          -  Impaired hepatic function in the absence of a diagnosis of primary sclerosing
             cholangitis

          -  Positive tests for antibodies indicating active or prior infection with HIV or
             hepatitis B (HBV) or C (HCV)

          -  Positive screening test for latent mycobacterium tuberculosis (TB) infection

          -  Demyelinating disease

          -  Received any investigational treatment within 12 weeks prior to initiation of study
             treatment

          -  Previous exposure to rhuMAb Beta7
Clinical trial NCT00385021 (phase 2, status: terminated)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5-fluorouracil, leucovorin, oxaliplatin, avastin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological proof of adenocarcinoma in primary colon or rectum tumor.

          -  Evidence of metastatic colorectal cancer or loco-regional recurrence or unresectable
             disease.

          -  Ages 18 to 86 years.

          -  Presence of at least one bi-dimensionally measurable disease with at least one
             diameter > or = 2 cm.

          -  WHO/ECOG performance status < 3 (0, 1, or 2)

          -  Prior treatment with oxaliplatin, 5-FU, or leucovorin permitted.

          -  Signed informed consent

        Exclusion Criteria:

          -  Peripheral sensory neuropathy > or = grade 3.

          -  Serum bilirubin (total) > 3 X ULN.

          -  Symptomatic or uncontrolled brain metastasis.

          -  Metastases limited to bone, pleural effusion, or ascites.

          -  Uncontrolled overt cardiac disease.

          -  Uncontrolled hypercalcemia.

          -  Uncontrolled infections.

          -  Uncontrolled hypertension (>180/110)

          -  History of GI perforation.

          -  History of arterial thromboembolic events.

          -  History of congestive heart failure.

          -  Patients taking warfarin (Coumadin).

          -  Patients who are pregnant.